Jounce Therapeutics (NASDAQ:JNCE) insider Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $25.06, for a total transaction of $113,897.70. Following the completion of the sale, the insider now owns 4,545 shares of the company’s stock, valued at $113,897.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Elizabeth Trehu also recently made the following trade(s):
- On Monday, March 5th, Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock. The stock was sold at an average price of $21.50, for a total transaction of $97,717.50.
NASDAQ JNCE traded down $1.23 during trading hours on Friday, hitting $18.48. 372,089 shares of the company’s stock traded hands, compared to its average volume of 340,821. The firm has a market capitalization of $619.00, a price-to-earnings ratio of -31.54 and a beta of 6.33. Jounce Therapeutics has a 52 week low of $11.05 and a 52 week high of $29.29.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC lifted its holdings in Jounce Therapeutics by 26.4% during the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares in the last quarter. Alps Advisors Inc. lifted its holdings in Jounce Therapeutics by 12.5% during the fourth quarter. Alps Advisors Inc. now owns 35,642 shares of the company’s stock valued at $454,000 after purchasing an additional 3,966 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Jounce Therapeutics by 10.8% during the fourth quarter. Bank of New York Mellon Corp now owns 45,889 shares of the company’s stock valued at $585,000 after purchasing an additional 4,467 shares in the last quarter. American International Group Inc. lifted its holdings in Jounce Therapeutics by 132.2% during the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after purchasing an additional 5,442 shares in the last quarter. Finally, OxFORD Asset Management LLP lifted its holdings in Jounce Therapeutics by 11.9% during the third quarter. OxFORD Asset Management LLP now owns 59,540 shares of the company’s stock valued at $927,000 after purchasing an additional 6,328 shares in the last quarter. Institutional investors own 90.30% of the company’s stock.
JNCE has been the subject of several recent research reports. Zacks Investment Research lowered shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Robert W. Baird set a $35.00 target price on shares of Jounce Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th.
COPYRIGHT VIOLATION NOTICE: “Jounce Therapeutics (JNCE) Insider Sells $113,897.70 in Stock” was posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/2018/04/06/jounce-therapeutics-inc-jnce-insider-sells-113897-70-in-stock/2037786.html.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.